Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Dual-signal Output Biosensor For The Detection Of Program Death-ligand 1 And Therapy Progress Monitoring Of Cancer.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Dual-signal Output Biosensor For The Detection Of Program Death-ligand 1 And Therapy Progress Monitoring Of Cancer.

Related Experiment Video

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Dual-signal output biosensor for the detection of program death-ligand 1 and therapy progress monitoring of cancer.

Heru Agung Saputra¹, Jae Heun Chung², Md Ali Zaber Sahin¹

¹Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan, 46241, South Korea.

Biosensors & Bioelectronics

|July 14, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new biosensor detects program death-ligand 1 (PD-L1) for cancer monitoring. This tool accurately measures PD-L1 levels in patients, aiding immunotherapy assessment and early cancer detection.

Keywords:

Cancer diagnosis Cancer immunotherapy Conducting polymer composite Dual-detection biosensor

More Related Videos

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

Related Experiment Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

Area of Science:

Biomedical Engineering
Analytical Chemistry
Cancer Research

Background:

Program death-ligand 1 (PD-L1) is a crucial immune checkpoint protein.
Monitoring PD-L1 levels is vital for immunotherapy efficacy and early cancer detection.
Existing methods for PD-L1 detection can be complex and time-consuming.

Purpose of the Study:

To develop a disposable dual-output biosensor for sensitive and specific detection of PD-L1.
To enable real-time monitoring of immunotherapy progress and facilitate early cancer diagnosis.
To evaluate PD-L1 as a superior biomarker compared to granzyme B and interferon-gamma.

Main Methods:

Fabrication of a biosensor using reduced graphene oxide composited with a carboxylated terthiophene polymer (rGO-pTBA) aptamer probe.

Program death-ligand 1

Amperometric detection of PD-L1 using a novel redox mediator (ortho-amino phenol para sulphonic acid).

Characterization of the sensing layer and validation of sensing performance using electrochemical and surface analysis.

Main Results:

The biosensor demonstrated high sensitivity with detection limits of 0.20 ± 0.001 pM for PD-L1.
Two dynamic ranges (0.5-100.0 pM and 100.0-500.0 pM) were established for PD-L1 quantification.
Significantly elevated sPD-L1 levels in lung cancer patients were observed, decreasing after immunotherapy, confirming therapy monitoring efficacy.
PD-L1 proved to be a more effective biomarker than granzyme B and interferon-gamma.

Conclusions:

The developed disposable biosensor offers a reliable and efficient platform for PD-L1 detection.
This technology holds promise for advancing immunotherapy monitoring and early cancer detection strategies.
PD-L1 is confirmed as a key biomarker for assessing cancer progression and therapeutic response.